ATE385253T1 - Nhibitor-resistente hcv ns3 protease - Google Patents

Nhibitor-resistente hcv ns3 protease

Info

Publication number
ATE385253T1
ATE385253T1 AT03770808T AT03770808T ATE385253T1 AT E385253 T1 ATE385253 T1 AT E385253T1 AT 03770808 T AT03770808 T AT 03770808T AT 03770808 T AT03770808 T AT 03770808T AT E385253 T1 ATE385253 T1 AT E385253T1
Authority
AT
Austria
Prior art keywords
protease
resistant
inhibitor
hcv
nhibitor
Prior art date
Application number
AT03770808T
Other languages
English (en)
Inventor
George Kukolj
Lisette Lagace
Martin Marquis
Daniel Lamarre
Arnim Pause
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of ATE385253T1 publication Critical patent/ATE385253T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • External Artificial Organs (AREA)
  • Materials For Photolithography (AREA)
AT03770808T 2002-10-29 2003-10-24 Nhibitor-resistente hcv ns3 protease ATE385253T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42194302P 2002-10-29 2002-10-29

Publications (1)

Publication Number Publication Date
ATE385253T1 true ATE385253T1 (de) 2008-02-15

Family

ID=32230287

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03770808T ATE385253T1 (de) 2002-10-29 2003-10-24 Nhibitor-resistente hcv ns3 protease

Country Status (13)

Country Link
US (1) US7208309B2 (de)
EP (1) EP1558730B1 (de)
JP (1) JP4295222B2 (de)
AT (1) ATE385253T1 (de)
AU (1) AU2003280239B2 (de)
CA (1) CA2498653C (de)
DE (1) DE60318954T2 (de)
DK (1) DK1558730T3 (de)
ES (1) ES2298585T3 (de)
IL (1) IL168254A (de)
MX (1) MXPA05004276A (de)
NZ (1) NZ540292A (de)
WO (1) WO2004039970A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000308A2 (en) * 2003-05-15 2005-01-06 Rigel Pharmaceuticals, Inc. Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c
WO2005042570A1 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Hcv ns3-ns4a protease resistance mutants
BRPI0506948B1 (pt) 2004-01-30 2018-09-18 Medivir Ab inibidores de serina protease ns-3 de hcv
AU2006235438A1 (en) * 2005-04-11 2006-10-19 Achillion Pharmaceuticals, Inc. Pharmaceutical compositions for and methods of inhibiting HCV replication
US7465537B2 (en) * 2005-05-01 2008-12-16 The Board Of Trustees Of The University Of Arkansas Compounds and methods for inhibiting hepatitis C virus replication
WO2007014174A2 (en) * 2005-07-25 2007-02-01 Gilead Sciences, Inc. Drug-resistant mutants of hepatitis c virus
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
EP1951748B1 (de) 2005-11-11 2013-07-24 Vertex Pharmaceuticals, Inc. Varianten des hepatitis-c-virus
EP2527474A1 (de) 2006-10-20 2012-11-28 Innogenetics N.V. Verfahren zur Analyse von Sequenzvariationen innerhalb des HCV-NS3/4A-Genombereichs
WO2008112108A1 (en) * 2007-03-09 2008-09-18 Merck & Co., Inc. In vivo hcv resistance to anti-viral inhibitors
WO2008121487A2 (en) 2007-03-29 2008-10-09 The Govt. Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Sevices. Live attenuated virus vaccines for la crosse virus and other bunyaviridae
EP2342336B1 (de) 2008-09-05 2016-12-14 President and Fellows of Harvard College Kontinuierliche gerichtete evolution von proteinen und nukleinsäuren
CA2825370A1 (en) 2010-12-22 2012-06-28 President And Fellows Of Harvard College Continuous directed evolution
EP2729489A1 (de) * 2011-07-06 2014-05-14 Gilead Sciences, Inc. Hcv-genotyp-3-replikons
WO2013006721A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Hcv genotype 4 replicons
EP3097196B1 (de) 2014-01-20 2019-09-11 President and Fellows of Harvard College Negativauswahl und stringenzmodulation in systemen der kontinuierlichen evolution
WO2016077052A2 (en) 2014-10-22 2016-05-19 President And Fellows Of Harvard College Evolution of proteases
WO2016168631A1 (en) 2015-04-17 2016-10-20 President And Fellows Of Harvard College Vector-based mutagenesis system
US10392674B2 (en) 2015-07-22 2019-08-27 President And Fellows Of Harvard College Evolution of site-specific recombinases
WO2017015559A2 (en) 2015-07-23 2017-01-26 President And Fellows Of Harvard College Evolution of bt toxins
WO2017019895A1 (en) 2015-07-30 2017-02-02 President And Fellows Of Harvard College Evolution of talens
WO2019010164A1 (en) 2017-07-06 2019-01-10 President And Fellows Of Harvard College Evolution of trna synthetases
US12060553B2 (en) 2017-08-25 2024-08-13 President And Fellows Of Harvard College Evolution of BoNT peptidases
US11624130B2 (en) 2017-09-18 2023-04-11 President And Fellows Of Harvard College Continuous evolution for stabilized proteins
WO2019241649A1 (en) 2018-06-14 2019-12-19 President And Fellows Of Harvard College Evolution of cytidine deaminases
AU2020252001B2 (en) 2019-03-29 2026-02-26 Trustees Of Boston University Chimeric antigen receptor (CAR) modulation
US11572565B2 (en) 2020-07-21 2023-02-07 Trustees Of Boston University Inducible control of gene expression

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843752A (en) * 1995-05-12 1998-12-01 Schering Corporation Soluble active hepatitis C virus protease
IT1277914B1 (it) * 1995-08-22 1997-11-12 Angeletti P Ist Richerche Bio Procedimento per produrre - in forma pura e in quantita' elevate - polipeptidi con l'attivita' proteolitica della proteasi ns3 di hcv, e
US5990276A (en) * 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6326137B1 (en) * 1999-06-25 2001-12-04 Schering Corporation Hepatitis C virus protease-dependent chimeric pestivirus
US20050074465A1 (en) * 1999-11-24 2005-04-07 Michael Houghton HCV fusion proteins with modified NS3 domains
US6986892B1 (en) * 1999-11-24 2006-01-17 Chiron Corporation Immunogenic Hepatitis C virus non-structural polypeptides
IL156058A0 (en) * 2000-12-22 2003-12-23 Boehringer Ingelheim Ca Ltd Self-replicating rna molecule from hepatitis c virus
WO2002068933A2 (en) * 2001-02-28 2002-09-06 The Scripps Research Institute Small molecule design against drug resistant mutants using directed evolution
WO2005042570A1 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Hcv ns3-ns4a protease resistance mutants

Also Published As

Publication number Publication date
DE60318954D1 (de) 2008-03-20
ES2298585T3 (es) 2008-05-16
US7208309B2 (en) 2007-04-24
EP1558730A1 (de) 2005-08-03
JP2006503584A (ja) 2006-02-02
CA2498653A1 (en) 2004-05-13
IL168254A (en) 2010-11-30
MXPA05004276A (es) 2005-08-03
WO2004039970A1 (en) 2004-05-13
DK1558730T3 (da) 2008-05-26
CA2498653C (en) 2010-12-14
JP4295222B2 (ja) 2009-07-15
DE60318954T2 (de) 2009-01-22
AU2003280239A1 (en) 2004-05-25
AU2003280239B2 (en) 2009-03-12
US20050019753A1 (en) 2005-01-27
EP1558730B1 (de) 2008-01-30
NZ540292A (en) 2006-09-29

Similar Documents

Publication Publication Date Title
DK1558730T3 (da) Inhibitorresistent HCV-NS3-protease
WO2004101602A3 (en) Hepatitis c inhibitor peptide analogs
TW200615275A (en) Hepatitis C inhibitor dipeptide analogs
IL162815A0 (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
IL152022A0 (en) Compounds useful as protease inhibitors and pharmaceutical compositions containing the same
WO2007016476A3 (en) Hepatitis c serine protease inhibitors and uses therefor
DE602005015834D1 (de) 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
DE122012000004I1 (de) Peptide als inhibitoren der NS3-Serinprotease des hepatitis c virus.
BR0211623A (pt) Agentes de contraste alvos multiméricos com base em peptìdeo
ATE547412T1 (de) Inhibitoren von serinproteasen, insbesondere hcv- ns3-ns4a-protease
UY27972A1 (es) Derivados de hidantoína
EA200400986A1 (ru) Гетероциклические трипептиды в качестве ингибиторов вируса гепатита c
CY1109779T1 (el) Αναστολεις της hcv ns-3 πρωτεασης σερινης
WO2003064455A3 (en) Macrocyclic peptides active against the hepatitis c virus
ATE512971T1 (de) Peptidanaloga als hepatitis c-hemmer
TW200508220A (en) Hepatitis C inhibitor compounds
SE0201976D0 (sv) Novel compounds
IL156774A0 (en) Inhibitors of cruzipain and other cysteine proteases
BRPI0410861A (pt) métodos e composições para a produção de aminoácidos
AU2003277891A1 (en) Hcv ns-3 serine protease inhibitors
Bennett et al. The identification of α-ketoamides as potent inhibitors of hepatitis c virus nS3-4a proteinase
WO2003095475A8 (en) Peptide compounds and their use as protease substrates
BRPI0416201A (pt) métodos para purificação de toxina coqueluche e peptìdios neles utilizáveis
GB0221169D0 (en) Crystal
ATE281522T1 (de) Sentrin-spezifische menschliche protease senp1

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1558730

Country of ref document: EP